EUVIMEDEUVIMED entdecken
Crossref

Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway

Yi Mao, Xinru Xie, Ting Jiang, Rui Chao, Tianhao Wan, Lei Sun, Guangxin Sun, Zihang Zhou, Weifeng Xu, Xuzhuo Chen, Shanyong Zhang

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Yi Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Stomatolo…. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Bone Resorption, Osteolysis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 2 Literaturangaben. Gefördert von: National Outstanding Youth Science Fund Project of National Natural Science Foundation of China, National Natural Science Foundation of China, Program of Shanghai Academic Research Leader.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inbonemetabolism,osteoclastsare the only cellscapableofresorbingbone. Hyperactivity of osteoclasts may lead to osteolytic disease like osteoporosis and arthritis. Although there are several drugs for the treatment of osteolytic diseases, they have limitations and a variety of side effects. An inhibitor of Janus kinase (JAK), XL019, has shown promising results in the treatment of myelofibrosis and other cancers. But whether it can functionally impact osteoclast activity has not been proven. In this study, the effects of XL019 on osteoclastogenesis and the mechanism pathway were investigated in vitro. It was found that XL019 could impair osteoclasts formation, interfere with bone resorption ability and downregulate the osteoclast-specific genes and proteins expression. Furthermore, Western blot and molecular docking studies demonstrated that XL019 inhibited RANKL-induced osteoclastogenesis by suppressing MAPK signaling. A molecular docking analysis explained how XL019 binds to MAPK pathway factors. In addition, titanium particles induced calvarial osteolysis in mice further confirming its beneficial effect on bone homeostasis in vivo. In conclusion, this study demonstrates that Osteoclastactivity canbeeffectivelyinhibitedby XL019viaMAPK signalingpathway,making it a promising alternative pharmacologicaltreatmentfor bone metabolicdisorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsBone ResorptionOsteolysisAnimalsMiceOsteoclastsMolecular Docking SimulationSignal TransductionOsteogenesisRANK LigandCell DifferentiationNF-kappa BNFATC Transcription Factors

Stichwörter der Autor:innen

Bone resorptionJAK inhibitorMAPK signaling pathwayOsteoclastXL019

Substanzen

Janus Kinase InhibitorsRANK LigandNF-kappa BNFATC Transcription Factors

Autor:innen und Institutionen

  • Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; College of Stomatology, Shanghai Jiao Tong University, Shanghai, China; National Center fo…
  • Department of Orthodontics, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Oral and Maxillofacial Surgery, China Medical University School and Hospital of Stomatology, Shenyang, Liaoning, China.
  • College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Förderung

  • National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Program of Shanghai Academic Research Leader
  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China

Zitieren

APA

Mao, Y., Xie, X., Jiang, T., Chao, R., Wan, T., Sun, L., Sun, G., Zhou, Z., Xu, W., Chen, X., & Zhang, S. (2023). Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115704

Vancouver

Mao Y, Xie X, Jiang T, Chao R, Wan T, Sun L, et al. Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115704

BibTeX
@article{Mao2023,
  author = {Mao, Yi and Xie, Xinru and Jiang, Ting and Chao, Rui and Wan, Tianhao and Sun, Lei and Sun, Guangxin and Zhou, Zihang and Xu, Weifeng and Chen, Xuzhuo and Zhang, Shanyong},
  title = {Xl019, a novel JAK inhibitor, suppressed osteoclasts differentiation induced by RANKL through MAPK signaling pathway},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115704}
}
Kostenlos starten →